UTILIZATION OF INHIBITORS OF EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)/PROSTATIC HYPERTROPHY

Details for Australian Patent Application No. 2003233223 (hide)

International Classifications

Event Publications

28 August 2003 Complete Application Filed

Priority application(s): 102 21 018.7 11.05.02 DE

15 January 2004 Application Open to Public Inspection

Published as AU-A-2003233223

27 January 2005 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

10 December 2009 Corrigenda

Applications OPI - Corrigenda Name Index Under the name Boehringer Ingelheim Pharma GmbH and Co. KG, Application No. 2003233223, under INID(43) correct the publication date to read 24.11.2003

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.